Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13258724 | 0.91 | DGAT1 (0.79) | DGAT1 | |
| SCHEMBL3393990 | 0.89 | DGAT1 (0.76) | DGAT1 | |
| SCHEMBL1424388 | 0.86 | DGAT1 (0.79) | DGAT1 | |
| SCHEMBL3395324 | 0.86 | DGAT1 (0.84) | DGAT1 | |
| SCHEMBL3393074 | 0.86 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL3393078 | 0.86 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL3393256 | 0.86 | DGAT1 (1.00) | DGAT1 | |
| SCHEMBL17907300 | 0.85 | DGAT1 (0.70) | DGAT1 | |
| SCHEMBL1424761 | 0.85 | DGAT1 (1.00) | DGAT1 | |
| Pf-04620110 SCHEMBL1425038 | 0.85 | DGAT1 (1.00) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4629808-B2 | — | — | 2011-02-09 | — | — | JP | claimed |
| JP-2010535190-A | — | — | 2010-11-18 | — | — | JP | claimed |
| EP-2185567-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | claimed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | claimed |
| WO-2010086820-A1 | 4-AMINO-5-OXO-7, 8-DIHYDROPYRIMIDO [5,4-F] [1,4] OXAZEPIN-6 (5H) -YL) PHENYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | PFIZER INC. (US) | 2010-08-05 | — | — | WO | disclosed |
| EP-2185567-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | PFIZER INC | 2009-05-28 | — | — | US | disclosed |
| WO-2009016462-A2 | SUBSTITUTED BICYCLOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137551-A1 | Substituted Bicyclolactam Compounds | CHRM2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CXCR2 | DGAT1 4238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.